Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark

Shares in Amgen fell by double digits Tuesday on long-awaited results for the company’s monthly MariTide shot, which is viewed as a potential rival to Wegovy and Zepbound.

Jonathan Gardner Member since November 15, 2023

Loading + Follow Following